78 results
8-K
EX-99.1
ARAV
Aravive Inc
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
prior to study entry. The statistical analysis plan called for a hierarchical approach for the assessment of PFS first in the bevacizumab-naïve population
8-K
swlte0 6vtt4sjpd
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
kr8qqo1p8h463hvtn7
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
e75se 1l7t
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
ny1b61
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
qfbbvfn6si 6tx7mij
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am